Selective benefit in high-risk patients, but won’t alter clinical practice

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 9
Volume 17
Issue 9

The basis for the increased risks of cytomegalovirus and P. carinii infections with DENSE-R-CHOP-14 was puzzling, said Dr. Zelenetz of Memorial Sloan Kettering Cancer Center.

The basis for the increased risks of cytomegalovirus and P. carinii infections with DENSE-R-CHOP-14 was puzzling, said Dr. Zelenetz of Memorial Sloan Kettering Cancer Center. “Increasing the dose density of rituximab should probably more effectively eliminate B cells. I understand that. But these are both T-cell-mediated infections.”

 

Dr. Zelenetz concurred that the study succeeded in meeting its primary endpoint of achieving more consistent rituximab pharmacokinetics. And DENSE-R-CHOP-14 does appear to selectively benefit higher-risk patients, although he cautioned that these were subset analyses.

 

“This is really very interesting data, but with the increased toxicity, should it change clinical practice today?” he asked. “I would say no, not at this time. I think randomized trials will be necessary to validate these findings.”

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content